Combination therapies with L-FMAU for the treatment of hepatitis B virus infection
L-FMAU administered in combination and/or alternation with FTC and in combination and/or alternation with an interferon, such as interferon alpha or interferon gamma provides superior therapy in humans against hepatitis B virus.
1 . A method for the treatment or prophylaxis of a human infected with hepatitis B virus comprising administering in combination or alternation an effective amount of:
β-L-FTC;
L-FMAU; and
interferon;
or their pharmaceutically acceptable salts or prodrugs, independently optionally in pharmaceutically acceptable carriers.
2 . The method of claim 1 , wherein the β-L-FTC is in substantially pure form.
3 . The method of claim 1 , wherein the β-L-FTC is at least 90% by weight of the β-L-isomer.
4 . The method of claim 1 , wherein the β-L-FTC is at least 95% by weight of the β-L-isomer.
5 . The method of claim 1 , wherein the interferon is selected from the group consisting of interferon alpha, pegylated interferon alpha, interferon alpha-2a, interferon alpha-2b, pegylated interferon alpha-2a, pegylated interferon alpha-2b ROFERON®-A (interferon alpha-2a), PEGASYS® (pegylated interferon alpha-2a), INTRON®A (Interferon alpha-2b), PEG-INTRON® (pegylated Interferon alpha-2b), interferon beta, interferon gamma, interferon tau, interferon omega, consensus interferon, INFERGEN (interferon alphacon-1), OMNIFERON (natural interferon), REBIF (interferon beta-1a), omega interferon, oral interferon alpha, interferon gamma-1b, SuperFeron (natural human multi-subtype IFN-alpha), and HuFeron (human IFN-beta).
6 . The method of claim 5 , wherein the interferon is interferon alpha.
7 . The method of claim 5 , wherein the interferon is interferon gamma.
8 . The method of claim 5 , wherein the interferon is interferon beta.